

Starpharma to receive A\$6.5M from Mundipharma and rights to VivaGel® BV

Melbourne, Australia; 14 August 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) today announces it has negotiated a commercial settlement agreement with Mundipharma in relation to the VivaGel® BV product.

Under the settlement:

- Starpharma will receive a US\$4.25M (~A\$6.54M) cash payment from Mundipharma.
- Starpharma will terminate its VivaGel® BV licence and supply agreements with Mundipharma, regaining all commercial rights to VivaGel® BV, enabling Starpharma to sign new marketing arrangements for the product.

Starpharma is well positioned to sign new commercial arrangements for VivaGel® BV with other healthcare companies in these territories, with commercial interest having already been expressed in the product. VivaGel® BV is now registered in more than 50 countries. Starpharma's decision to terminate this agreement follows the recently announced sale of Mundipharma's consumer health product portfolio to iNova Pharmaceuticals.

VivaGel® BV is a novel, non-antibiotic vaginal gel developed in Australia by Starpharma for both the treatment of bacterial vaginosis (BV) and the prevention of recurrent BV and its symptoms. BV is the most common vaginal infection worldwide, affecting one in three women globally. BV is associated with causing complications related to the reproductive health of women.

Dr Jackie Fairley, CEO of Starpharma, commented: "Starpharma is pleased to monetise the VivaGel® BV licence following negotiations with Mundipharma over recent months. The arrangement involves a cash payment of US\$4.25M (A\$6.5M), a substantial financial contribution to Starpharma. This cash payment is in addition to the US\$3.1M in milestones already received from Mundipharma for the product. This commercial development represents a positive step towards expanding VivaGel® BV sales, with Starpharma now free to engage with healthcare companies that have a strong consumer franchise and have already expressed interest in VivaGel® BV."

VivaGel® BV is an Australian innovation that continues to be marketed as Fleurstat BVgel by Aspen in Australia and New Zealand.

About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is a biopharmaceutical company focussed on the development of pharmaceutical and medical products for unmet patient needs, including in the areas of oncology and infectious diseases.

Starpharma's innovative technology is based on proprietary polymers called dendrimers, which are precise, synthetically manufactured, nanoscale molecules. The unique properties of dendrimers – including their size, structure, high degree of branching, polyvalency, and water solubility – are advantageous in medical and pharmaceutical applications.

Starpharma uses its dendrimer technology to develop novel therapeutics and to improve the performance of existing pharmaceuticals. Starpharma's portfolio includes multiple clinical stage oncology products, which utilise its Dendrimer Enhanced Product ("DEP[®]") drug delivery technology; and marketed products, including VIRALEZE™ and VivaGel[®] BV, which utilise SPL7013, a proprietary dendrimer with antimicrobial properties.

Starpharma's DEP[®] drug delivery platform is being used to enhance the effectiveness of existing and novel therapies and to reduce drug-related toxicities through controlled and specified drug delivery.

In addition to Starpharma's internal DEP[®] programs, Starpharma has multiple DEP[®] partnerships with international biopharmaceutical companies including AstraZeneca (oncology); MSD (antibody drug conjugates); Chase Sun (anti-infectives); and other world leading pharmaceutical companies. Due to the broad applicability and optionality of Starpharma's DEP[®] platform, partnered DEP[®] programs have the potential to generate significant future milestones and royalties.

Starpharma's topical antiviral nasal spray, VIRALEZE™, is now registered in more than 35 countries*, including in Europe, in the UK, and in Asia. Starpharma's novel non-antibiotic vaginal gel, VivaGel[®] BV, for treatment of bacterial vaginosis (BV) and prevention of recurrent BV, is registered in more than 50 countries, including in the UK, in Europe, in Southeast Asia, South Africa, Australia and New Zealand.

Starpharma.com | [Twitter](#) | [LinkedIn](#)

Media: Sumit Media

Grant Titmus
Mob: +61 419 388 161
grant@sumitmedia.com.au

Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer
Justin Cahill, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas.

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.